EAST ST. LOUIS, Ill. – German drugmaker Boehringer Ingelheim has agreed to pay $650 million to settle thousands of U.S. claims questioning the marketing and safety of its popular blood thinner Pradaxa.
The company said Wednesday that it expects the settlement to resolve roughly 4,000 claims, with the payout per case averaging about $162,500.
The plaintiffs argued that the company didn’t adequately warn Pradaxa users of risks that included severe or, in many cases, fatal bleeding.
Boehringer Ingelheim released a statement saying it “resolutely” stands behind Pradaxa and “believed from the outset that the plaintiffs’ claims lacked any merit.”
The company says it was confident it would have prevailed in court but agreed to a settlement to avoid possibly years of litigation.
The settlement was filed in U.S. District Court in East St. Louis, Illinois.